Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/8/2025

Treatment of C. difficile Infection with Ileus

Initial Assessment and Management

  • The Infectious Diseases Society of America recommends that patients with C. difficile infection and ileus receive vancomycin 500 mg orally four times daily plus intravenous metronidazole 500 mg every 8 hours, with the addition of rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as a retention enema if ileus is severe 1, 2
  • Patients with CDI and ileus represent a fulminant form of the disease, characterized by severely disturbed bowel function that may progress to toxic megacolon, shock, and high mortality 1
  • Early detection of shock and aggressive management of underlying organ dysfunction are essential for improved outcomes, and supportive measures should include intravenous fluid resuscitation, electrolyte replacement, and albumin supplementation in patients with severe hypoalbuminemia (3)

Antibiotic Treatment

  • The American College of Gastroenterology recommends vancomycin 500 mg orally four times daily for 10-14 days for fulminant CDI with ileus, concurrently with intravenous metronidazole 500 mg every 8 hours, and adding rectal vancomycin 500 mg in approximately 100 mL normal saline every 6 hours as a retention enema if ileus is severe 1, 2
  • IV metronidazole achieves therapeutic concentrations in inflamed colonic tissue, and rectal vancomycin provides direct delivery of the drug to the affected area 1, 2

Surgical Considerations

  • Early surgical consultation is essential for patients with fulminant CDI and ileus, with indicators for possible surgical intervention including rising WBC count, rising lactate level, progressive organ failure, and worsening abdominal distension 1, 2
  • Surgical options include subtotal colectomy with end ileostomy and diverting loop ileostomy with colonic lavage 1, 2

Alternative and Adjunctive Therapies

  • The Society for Healthcare Epidemiology of America recommends considering intravenous tigecycline, intravenous immunoglobulins, and bezlotoxumab for patients not responding to standard therapy 1, 2, 5

Prevention of Recurrence

  • The American College of Gastroenterology recommends extended pulsed vancomycin regimen, fidaxomicin, and fecal microbiota transplantation for patients at high risk of recurrence 5, 6, 7

Monitoring and Follow-up

  • Monitor for clinical improvement, including decreased abdominal distension, resolution of ileus, normalization of WBC count and lactate levels, and improvement in vital signs 1, 3, 8